Skip To Main Content
P.L. Bedard on Muck Rack

P.L. Bedard

As seen in: ScienceDirect
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to P.L. Bedard’s profile

Articles by P.L. Bedard

Polypeptide nanomicelles co-deliver PLK1 and BCL-2/xL inhibitors for synergetic therapy of brain tumor

|
By P.L. Bedard, D. Hanahan, Y. Xing, Y. Xiong
| ScienceDirect Verified
The identification of molecular targets and the enriching knowledge of their functions related with cancers have revolutionized the clinical practice of molecular targeted therapy for various cancer patients [1], [2], [3].
Open in Who Shared Issue with article?

Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer

|
By P.L. Bedard, D.M. Hyman, M.S. Davids, L.L. Siu
| ScienceDirect Verified
Under a Creative Commons license open access Introduction Targeted therapies like tyrosine kinase inhibitors (TKIs) have brought precision medicine to the forefront of modern oncology.
Open in Who Shared Issue with article?

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study

|
By Gustave Roussy, Villejuif Cedex, A. Gazzah, P.L. Bedard
| annalsofoncology.org
HIGHLIGHTS • Tusamitamab ravtansine (SAR408701) is a humanized monoclonal antibody covalently linked to a cytotoxic maytansinoid • This potential first-in-class antibody-drug conjugate selectively targets tumor cells expressing CEACAM5 • 100 mg/m2 IV every two weeks is the maximum tolerated dose of tusamitamab ravtansine; reversible keratopathy being the dose limiting toxicity • Tusamitamab ravtansine has a favorable safety profile with infrequent hematological toxicities compared with that...
Open in Who Shared Issue with article?
Show More